FLX475
- Generic Name
- FLX475
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
FLX475 in Combination With Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04894994
- Locations
- 🇺🇸
Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 20
- Registration Number
- NCT04768686
- Locations
- 🇰🇷
The Catholic University of Korea St. Vincent Hospital, Suwon-si,, Gyeonggi-do, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of
🇰🇷Hanllym University Medical Center, Anyang-si, Gyeonggi-do, Korea, Republic of
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT03674567
- Locations
- ðŸ‡ðŸ‡°
Prince of Wales Hospital, Shatin, Hong Kong
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸University of Washington, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.